https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-10 / J Hematol Oncol 2010 Feb;3:7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-10 / J Hematol Oncol 2010 Feb;3:72010-02-10 00:00:002010-02-10 00:00:00Ovarian cancer immunotherapy: opportunities, progresses and challenges
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-09 / Immunol. Cell Biol. 2010 Jul;88(5):596-604
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-09 / Immunol. Cell Biol. 2010 Jul;88(5):596-6042010-02-09 00:00:002019-02-15 08:44:06Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-04 / Cancer Immunol. Immunother. 2010 Jul;59(7):989-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-04 / Cancer Immunol. Immunother. 2010 Jul;59(7):989-992010-02-04 00:00:002019-02-15 09:21:48The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-03 / Int J Radiat Oncol Biol Phys 2010 Nov;78(3):828-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-03 / Int J Radiat Oncol Biol Phys 2010 Nov;78(3):828-352010-02-03 00:00:002010-02-03 00:00:00Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-01 / J. Immunother. 2010 Feb-Mar;33(2):155-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-01 / J. Immunother. 2010 Feb-Mar;33(2):155-662010-02-01 00:00:002019-02-15 08:44:00Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-612010-01-30 00:00:002019-02-15 08:50:36What’s the place of immunotherapy in malignant mesothelioma treatments?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-29 / Curr. Opin. Immunol. 2010 Feb;22(1):137-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-29 / Curr. Opin. Immunol. 2010 Feb;22(1):137-442010-01-29 00:00:002019-02-15 08:44:07Presentation of tumour antigens by dendritic cells and challenges faced
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-25 / Oncogene 2010 Apr;29(15):2205-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-25 / Oncogene 2010 Apr;29(15):2205-162010-01-25 00:00:002019-02-15 09:21:49Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-06 / BMC Cancer 2010 Jan;10:5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-06 / BMC Cancer 2010 Jan;10:52010-01-06 00:00:002019-02-15 08:43:59Tocotrienols are good adjuvants for developing cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):195-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):195-92010-01-01 00:00:002019-02-15 08:59:37Monitoring immune responses after glioma vaccine immunotherapy
